Myocarditis in the UK: Moderna vs. the Virus! NEW Nature Medicine Paper
What this video covers
Dr. Vinay Prasad dissects a large English study (Patone et al., published in Nature Medicine) that used the country’s national immunization database — roughly 43 million people aged 13 and older — to compare the risk of myocarditis after COVID-19 vaccination versus after COVID-19 infection. The study employed a self-controlled case series design, comparing myocarditis rates in the 1–28 days after vaccination or a positive test against each person’s own baseline periods.
Prasad zeroes in on the subgroup finding he considers most important: in men under 40, the number of excess myocarditis events per million was higher after a second dose of Moderna (roughly 97 per million) than after a positive COVID-19 test (roughly 16 per million). His argument is that while the study’s headline message — that infection carried more myocarditis risk overall — was true for the population as a whole, it obscured a subgroup where the risk-benefit math looked unfavorable for the vaccine, particularly for young men receiving Moderna.
From this, Prasad builds his recurring case against one-size-fits-all vaccine policy: young men, he argues, were being pushed toward a product and dose schedule whose cardiac risk for them exceeded the cardiac risk of the infection itself, and regulators should have stratified recommendations by age, sex, and product rather than recommending uniformly.
He also flags a methodological asymmetry he says favored the vaccine in the comparison: the study’s infection-side denominator counted only people with a documented positive test, whereas the true denominator includes everyone who was infected — many of whom never sought testing — so the post-infection myocarditis rate was likely overstated. On the vaccine side, he notes, the numerator came from passive surveillance, which misses cases. He says he asked the authors to perform a seroprevalence-corrected analysis, and argues the headline comparison would look even more favorable to his reading with that correction.
Key points
- Prasad summarizes the Patone et al. study design: England’s national immunization records for ~43 million people aged 13+, cross-referenced with infection, hospital, and death records, using a self-controlled case series method.
- He highlights the subgroup result: in men under 40, excess myocarditis events per million were higher after a second Moderna dose (~97/million) than after a positive COVID-19 test (~16/million).
- According to Prasad, this subgroup finding was the story — he argues that averaging risk across “16-year-old boys with their great grandma” hid unfavorable risk-benefit math for young men.
- He contends the finding, specific to the original higher-dose Moderna regimen during the Delta era, warranted restricting or deprioritizing Moderna for younger men — as several European countries in fact did.
- Prasad criticizes U.S. regulators and advisory committees for maintaining uniform recommendations despite subgroup data he says demanded stratification.
- He frames the episode as evidence that “the only reason smart people would have a one-size-fits-all policy” is hard to explain on scientific grounds — while stopping short of asserting a motive, he raises the question of manufacturer interests.
- Prasad argues the study’s infection-side denominator was likely underestimated — counting only documented positive tests rather than all infections — which would inflate the apparent post-infection myocarditis rate; he says he asked the authors for a seroprevalence-corrected analysis.
- Context the video acknowledges implicitly but does not center: the study authors’ overall conclusion was that, across the full population, myocarditis risk after infection exceeded risk after vaccination — Prasad’s focus is deliberately on the exception.